Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections

{ 'indexed': {'date-parts': [[2023, 4, 26]], 'date-time': '2023-04-26T05:05:39Z', 'timestamp': 1682485539097}, 'reference-count': 143, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2023, 4, 25]], 'date-time': '2023-04-25T00:00:00Z', 'timestamp': 1682380800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springernature.com/gp/researchers/text-and-data-mining'}, { 'start': { 'date-parts': [[2023, 4, 25]], 'date-time': '2023-04-25T00:00:00Z', 'timestamp': 1682380800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springernature.com/gp/researchers/text-and-data-mining'}], 'funder': [ { 'DOI': '10.13039/100006492', 'name': 'Division of Intramural Research, National Institute of Allergy and Infectious ' 'Diseases', 'doi-asserted-by': 'publisher', 'award': ['R01AI146160']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'DOI': '10.1007/s11095-023-03520-1', 'type': 'journal-article', 'created': {'date-parts': [[2023, 4, 25]], 'date-time': '2023-04-25T20:27:25Z', 'timestamp': 1682454445000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory ' 'Viral Infections', 'prefix': '10.1007', 'author': [ {'given': 'Ching-Yee', 'family': 'Loo', 'sequence': 'first', 'affiliation': []}, {'given': 'Wing-Hin', 'family': 'Lee', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-1438-6990', 'authenticated-orcid': False, 'given': 'Qi Tony', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2023, 4, 25]]}, 'reference': [ { 'key': '3520_CR1', 'doi-asserted-by': 'publisher', 'first-page': '100986', 'DOI': '10.1016/j.eclinm.2021.100986', 'volume': '37', 'author': 'X Jin', 'year': '2021', 'unstructured': 'Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, Zhang J, Wang X, Wang G. ' 'Global burden of upper respiratory infections in 204 countries and ' 'territories, from 1990 to 2019. EClinicalMedicine. 2021;37:100986.', 'journal-title': 'EClinicalMedicine'}, { 'key': '3520_CR2', 'doi-asserted-by': 'publisher', 'first-page': '117863611875865', 'DOI': '10.1177/1178636118758651', 'volume': '11', 'author': 'D Assane', 'year': '2018', 'unstructured': 'Assane D, Makhtar C, Abdoulaye D, Amary F, Djibril B, Amadou D, Niokhor ' 'DJB, Amadou D, Cheikh L, Ndongo D, Mbayame N, Lamine F, Bouh BCS. Viral ' 'and Bacterial Etiologies of Acute Respiratory Infections Among Children ' 'Under 5 Years in Senegal. Microbiol Insights. 2018;11:1178636118758651.', 'journal-title': 'Microbiol Insights'}, { 'key': '3520_CR3', 'doi-asserted-by': 'publisher', 'first-page': '6741290', 'DOI': '10.1155/2021/6741290', 'volume': '2021', 'author': 'M Ftouh', 'year': '2021', 'unstructured': 'Ftouh M, Kalboussi N, Abid N, Sfar S, Mignet N, Bahloul B. Contribution ' 'of Nanotechnologies to Vaccine Development and Drug Delivery against ' 'Respiratory Viruses. PPAR Res. 2021;2021:6741290.', 'journal-title': 'PPAR Res'}, { 'key': '3520_CR4', 'doi-asserted-by': 'publisher', 'first-page': '661', 'DOI': '10.1016/j.jconrel.2022.03.051', 'volume': '345', 'author': 'D Baldassi', 'year': '2022', 'unstructured': 'Baldassi D, Ambike S, Feuerherd M, Cheng CC, Peeler DJ, Feldmann DP, ' 'Porras-Gonzalez DL, Wei X, Keller LA, Kneidinger N, Stoleriu MG, Popp A, ' 'Burgstaller G, Pun SH, Michler T, Merkel OM. Inhibition of SARS-CoV-2 ' 'replication in the lung with siRNA/VIPER polyplexes. J Control Release. ' '2022;345:661–74.', 'journal-title': 'J Control Release'}, { 'key': '3520_CR5', 'doi-asserted-by': 'crossref', 'unstructured': 'Dong C, Wang Y, Gonzalez GX, Ma Y, Song Y, Wang S, Kang SM, Compans RW, ' 'Wang BZ. Intranasal vaccination with influenza HA/GO-PEI nanoparticles ' 'provides immune protection against homo- and heterologous strains. Proc ' 'Natl Acad Sci USA. 2021;118(19):e2024998118.', 'DOI': '10.1073/pnas.2024998118'}, { 'issue': '27', 'key': '3520_CR6', 'doi-asserted-by': 'publisher', 'first-page': '2603', 'DOI': '10.1056/NEJMoa2034577', 'volume': '383', 'author': 'FP Polack', 'year': '2020', 'unstructured': 'Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez ' 'JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, ' 'Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt ' 'LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, ' 'Dormitzer PR, Şahin U, Jansen KU, Gruber WC. Safety and Efficacy of the ' 'BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.', 'journal-title': 'N Engl J Med'}, { 'issue': '5', 'key': '3520_CR7', 'doi-asserted-by': 'publisher', 'first-page': '403', 'DOI': '10.1056/NEJMoa2035389', 'volume': '384', 'author': 'LR Baden', 'year': '2020', 'unstructured': 'Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, ' 'Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, ' 'Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, ' 'Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, ' 'Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han ' 'S, Ivarsson M, Miller J, Zaks T. Efficacy and Safety of the mRNA-1273 ' 'SARS-CoV-2 Vaccine. N Engl J Med. 2020;384(5):403–16.', 'journal-title': 'N Engl J Med'}, { 'key': '3520_CR8', 'doi-asserted-by': 'crossref', 'unstructured': 'Tulbah AS, Lee WH. Physicochemical characteristics and in vitro ' 'toxicity/Anti-SARS-CoV-2 activity of Favipiravir solid lipid ' 'nanoparticles (SLNs). Pharmaceuticals (Basel, Switzerland). ' '2021;14(10):1059.', 'DOI': '10.3390/ph14101059'}, { 'key': '3520_CR9', 'doi-asserted-by': 'crossref', 'unstructured': 'Sahakijpijarn S, Moon C, Koleng JJ, Christensen DJ, Williams Iii RO. ' 'Development of remdesivir as a dry powder for inhalation by Thin Film ' 'Freezing. Pharmaceutics. 2020;12(11):1002.', 'DOI': '10.3390/pharmaceutics12111002'}, { 'issue': '4', 'key': '3520_CR10', 'doi-asserted-by': 'publisher', 'first-page': '382', 'DOI': '10.1053/rmed.2002.1457', 'volume': '97', 'author': 'DA Groneberg', 'year': '2003', 'unstructured': 'Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of ' 'pulmonary drug delivery. Respir Med. 2003;97(4):382–7.', 'journal-title': 'Respir Med'}, { 'issue': '12', 'key': '3520_CR11', 'doi-asserted-by': 'publisher', 'first-page': '865', 'DOI': '10.2217/nnm-2021-0447', 'volume': '17', 'author': 'CY Loo', 'year': '2022', 'unstructured': 'Loo CY, Lee WH. Nanotechnology-based therapeutics for targeting ' 'inflammatory lung diseases. Nanomedicine (Lond). 2022;17(12):865–79.', 'journal-title': 'Nanomedicine (Lond)'}, { 'key': '3520_CR12', 'doi-asserted-by': 'publisher', 'first-page': '105987', 'DOI': '10.1016/j.rmed.2020.105987', 'volume': '167', 'author': 'A Ari', 'year': '2020', 'unstructured': 'Ari A. Practical strategies for a safe and effective delivery of ' 'aerosolized medications to patients with COVID-19. Respir Med. ' '2020;167:105987.', 'journal-title': 'Respir Med'}, { 'key': '3520_CR13', 'doi-asserted-by': 'publisher', 'first-page': '342', 'DOI': '10.1016/B978-0-12-386454-3.00099-3', 'volume-title': 'Encyclopedia of Toxicology', 'author': 'GM Fent', 'year': '2014', 'unstructured': 'Fent GM. Avermectin. In: Wexler P, editor. Encyclopedia of Toxicology. ' '3rd ed. Oxford: Academic Press; 2014. p. 342–4.', 'edition': '3'}, { 'issue': '12', 'key': '3520_CR14', 'doi-asserted-by': 'publisher', 'first-page': '100262', 'DOI': '10.1016/j.jics.2021.100262', 'volume': '98', 'author': 'SS Kapale', 'year': '2021', 'unstructured': 'Kapale SS, Chaudhari HK. Niclosamide & challenges in chemical ' 'modifications: A broad review on enhancement of solubility. J Indian ' 'Chem Soc. 2021;98(12):100262.', 'journal-title': 'J Indian Chem Soc'}, { 'key': '3520_CR15', 'doi-asserted-by': 'crossref', 'unstructured': 'Tai W, Chow MY, Chang RY, Tang P, Gonda I, MacArthur RB, Chan H-K, Kwok ' 'PC. Nebulised isotonic hydroxychloroquine aerosols for potential ' 'treatment of COVID-19. Pharmaceutics. 2021;13(8):1260.', 'DOI': '10.3390/pharmaceutics13081260'}, { 'issue': '7', 'key': '3520_CR16', 'doi-asserted-by': 'publisher', 'first-page': '7760', 'DOI': '10.1021/acsnano.0c04006', 'volume': '14', 'author': 'G Chauhan', 'year': '2020', 'unstructured': 'Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO. ' 'Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS ' 'Nano. 2020;14(7):7760–82.', 'journal-title': 'ACS Nano'}, { 'key': '3520_CR17', 'doi-asserted-by': 'publisher', 'first-page': '114482', 'DOI': '10.1016/j.jpba.2021.114482', 'volume': '209', 'author': 'B Várnai', 'year': '2022', 'unstructured': 'Várnai B, Malanga M, Sohajda T, Béni S. Molecular interactions in ' 'remdesivir-cyclodextrin systems. J Pharm Biomed Anal. 2022;209:114482.', 'journal-title': 'J Pharm Biomed Anal'}, { 'issue': '9', 'key': '3520_CR18', 'doi-asserted-by': 'publisher', 'first-page': '2964', 'DOI': '10.1021/jm900080g', 'volume': '52', 'author': 'DA DeGoey', 'year': '2009', 'unstructured': 'DeGoey DA, Grampovnik DJ, Flosi WJ, Marsh KC, Wang XC, Klein LL, ' 'McDaniel KF, Liu Y, Long MA, Kati WM, Molla A, Kempf DJ. Water-Soluble ' 'Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors ' 'Lopinavir and Ritonavir. J Med Chem. 2009;52(9):2964–70.', 'journal-title': 'J Med Chem'}, { 'issue': '4', 'key': '3520_CR19', 'doi-asserted-by': 'publisher', 'first-page': '1362', 'DOI': '10.1016/j.xphs.2016.01.017', 'volume': '105', 'author': 'N Goodarzi', 'year': '2016', 'unstructured': 'Goodarzi N, Barazesh Morgani A, Abrahamsson B, Cristofoletti R, Groot ' 'DW, Langguth P, Mehta MU, Polli JE, Shah VP, Dressman JB. Biowaiver ' 'Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. J ' 'Pharm Sci. 2016;105(4):1362–9.', 'journal-title': 'J Pharm Sci'}, { 'issue': '4', 'key': '3520_CR20', 'doi-asserted-by': 'publisher', 'first-page': '562', 'DOI': '10.1038/s41564-020-0688-y', 'volume': '5', 'author': 'M Letko', 'year': '2020', 'unstructured': 'Letko M, Marzi A, Munster V. Functional assessment of cell entry and ' 'receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat ' 'Microbiol. 2020;5(4):562–9.', 'journal-title': 'Nat Microbiol'}, { 'issue': '1', 'key': '3520_CR21', 'doi-asserted-by': 'publisher', 'first-page': '3', 'DOI': '10.1038/s41580-021-00418-x', 'volume': '23', 'author': 'CB Jackson', 'year': '2022', 'unstructured': 'Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry ' 'into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20.', 'journal-title': 'Nat Rev Mol Cell Biol'}, { 'issue': '12', 'key': '3520_CR22', 'doi-asserted-by': 'publisher', 'first-page': '1654', 'DOI': '10.1016/S1473-3099(21)00396-0', 'volume': '21', 'author': 'S Wu', 'year': '2021', 'unstructured': 'Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan ' 'P, Wang B, Chen C, Chen Y, Song X, Wang Y, Si W, Sun T, Wang X, Hou L, ' 'Chen W. Safety, tolerability, and immunogenicity of an aerosolised ' 'adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: ' 'preliminary report of an open-label and randomised phase 1 clinical ' 'trial. Lancet Infect Dis. 2021;21(12):1654–64.', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '8', 'key': '3520_CR23', 'doi-asserted-by': 'publisher', 'first-page': '739', 'DOI': '10.1016/S2213-2600(22)00087-X', 'volume': '10', 'author': 'JX Li', 'year': '2022', 'unstructured': 'Li JX, Wu SP, Guo XL, Tang R, Huang BY, Chen XQ, Chen Y, Hou LH, Liu JX, ' 'Zhong J, Pan HX, Shi FJ, Xu XY, Li ZP, Zhang XY, Cui LB, Tan WJ, Chen W, ' 'Zhu FC. Safety and immunogenicity of heterologous boost immunisation ' 'with an orally administered aerosolised Ad5-nCoV after two-dose priming ' 'with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, ' 'open-label, single-centre trial. Lancet Respir Med. 2022;10(8):739–48.', 'journal-title': 'Lancet Respir Med'}, { 'issue': '6523', 'key': '3520_CR24', 'doi-asserted-by': 'publisher', 'first-page': '1473', 'DOI': '10.1126/science.abe3255', 'volume': '370', 'author': 'M Schoof', 'year': '2020', 'unstructured': 'Schoof M, Faust B, Saunders RA, Sangwan S, Rezelj V, Hoppe N, Boone M, ' 'Billesbølle CB, Puchades C, Azumaya CM, Kratochvil HT, Zimanyi M, ' 'Deshpande I, Liang J, Dickinson S, Nguyen HC, Chio CM, Merz GE, Thompson ' 'MC, Diwanji D, Schaefer K, Anand AA, Dobzinski N, Zha BS, Simoneau CR, ' 'Leon K, White KM, Chio US, Gupta M, Jin M, Li F, Liu Y, Zhang K, Bulkley ' 'D, Sun M, Smith AM, Rizo AN, Moss F, Brilot AF, Pourmal S, Trenker R, ' 'Pospiech T, Gupta S, Barsi-Rhyne B, Belyy V, Barile-Hill AW, Nock S, Liu ' 'Y, Krogan NJ, Ralston CY, Swaney DL, García-Sastre A, Ott M, Vignuzzi M, ' 'Walter P, Manglik A. An ultrapotent synthetic nanobody neutralizes ' 'SARS-CoV-2 by stabilizing inactive Spike. Science (New York, NY). ' '2020;370(6523):1473–9.', 'journal-title': 'Science (New York, NY)'}, { 'key': '3520_CR25', 'doi-asserted-by': 'crossref', 'unstructured': 'Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, ' 'Reed DS, Crossland NA, Shi Y, Duprex WP. Inhalable Nanobody (PiN-21) ' 'prevents and treats SARS-CoV-2 infections in Syrian hamsters at ' 'ultra-low doses. Sci Adv. 2021;7(22): eabh0319.', 'DOI': '10.1126/sciadv.abh0319'}, { 'issue': '1', 'key': '3520_CR26', 'doi-asserted-by': 'publisher', 'first-page': '2047144', 'DOI': '10.1080/19420862.2022.2047144', 'volume': '14', 'author': 'TJ Esparza', 'year': '2022', 'unstructured': 'Esparza TJ, Chen Y, Martin NP, Bielefeldt-Ohmann H, Bowen RA, Tolbert ' 'WD, Pazgier M, Brody DL. Nebulized delivery of a broadly neutralizing ' 'SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and ' 'pathological disease in a Syrian hamster model of COVID-19. MAbs. ' '2022;14(1):2047144.', 'journal-title': 'MAbs'}, { 'key': '3520_CR27', 'doi-asserted-by': 'crossref', 'unstructured': 'Gai J, Ma L, Li G, Zhu M, Qiao P, Li X, Zhang H, Zhang Y, Chen Y, Ji W, ' 'Zhang H, Cao H, Li X, Gong R, Wan Y. A potent neutralizing nanobody ' 'against SARS-CoV-2 with inhaled delivery potential. MedComm (2020). ' '2021;2(1):101–13.', 'DOI': '10.1002/mco2.60'}, { 'issue': '1', 'key': '3520_CR28', 'doi-asserted-by': 'publisher', 'first-page': '5469', 'DOI': '10.1038/s41467-021-25480-z', 'volume': '12', 'author': 'J Huo', 'year': '2021', 'unstructured': 'Huo J, Mikolajek H, Le Bas A, Clark JJ, Sharma P, Kipar A, Dormon J, ' 'Norman C, Weckener M, Clare DK, Harrison PJ, Tree JA, Buttigieg KR, ' 'Salguero FJ, Watson R, Knott D, Carnell O, Ngabo D, Elmore MJ, ' 'Fotheringham S, Harding A, Moynié L, Ward PN, Dumoux M, Prince T, Hall ' 'Y, Hiscox JA, Owen A, James W, Carroll MW, Stewart JP, Naismith JH, ' 'Owens RJ. A potent SARS-CoV-2 neutralising nanobody shows therapeutic ' 'efficacy in the Syrian golden hamster model of COVID-19. Nat Commun. ' '2021;12(1):5469.', 'journal-title': 'Nat Commun'}, { 'issue': '8', 'key': '3520_CR29', 'doi-asserted-by': 'publisher', 'first-page': '1389', 'DOI': '10.1016/j.cell.2022.03.009', 'volume': '185', 'author': 'C Li', 'year': '2022', 'unstructured': 'Li C, Zhan W, Yang Z, Tu C, Hu G, Zhang X, Song W, Du S, Zhu Y, Huang K, ' 'Kong Y, Zhang M, Mao Q, Gu X, Zhang Y, Xie Y, Deng Q, Song Y, Chen Z, Lu ' 'L, Jiang S, Wu Y, Sun L, Ying T. Broad neutralization of SARS-CoV-2 ' 'variants by an inhalable bispecific single-domain antibody. Cell. ' '2022;185(8):1389-1401.e1318.', 'journal-title': 'Cell'}, { 'issue': '12', 'key': '3520_CR30', 'doi-asserted-by': 'publisher', 'first-page': '103479', 'DOI': '10.1016/j.isci.2021.103479', 'volume': '24', 'author': 'S Ndeupen', 'year': '2021', 'unstructured': 'Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyártó BZ. The ' 'mRNA-LNP platform’s lipid nanoparticle component used in preclinical ' 'vaccine studies is highly inflammatory. iScience. 2021;24(12):103479.', 'journal-title': 'iScience.'}, { 'key': '3520_CR31', 'doi-asserted-by': 'crossref', 'unstructured': 'Suberi A, Grun MK, Mao T, Israelow B, Reschke M, Grundler J, Akhtar L, ' 'Lee T, Shin K, Piotrowski-Daspit AS, Homer RJ, Iwasaki A, Suh HW, ' 'Saltzman WM. Inhalable polymer nanoparticles for versatile mRNA delivery ' 'and mucosal vaccination. bioRxiv. 2022.', 'DOI': '10.1101/2022.03.22.485401'}, { 'issue': '1', 'key': '3520_CR32', 'doi-asserted-by': 'publisher', 'first-page': '336', 'DOI': '10.1016/j.matt.2021.09.022', 'volume': '5', 'author': 'Z Wang', 'year': '2022', 'unstructured': 'Wang Z, Xiang L, Lin F, Cai Z, Ruan H, Wang J, Liang J, Wang F, Lu M, ' 'Cui W. Inhaled ACE2-engineered microfluidic microsphere for ' 'intratracheal neutralization of COVID-19 and calming of the cytokine ' 'storm. Matter. 2022;5(1):336–62.', 'journal-title': 'Matter'}, { 'issue': '9', 'key': '3520_CR33', 'doi-asserted-by': 'publisher', 'first-page': '2840', 'DOI': '10.1111/all.14850', 'volume': '76', 'author': 'M Khaitov', 'year': '2021', 'unstructured': 'Khaitov M, Nikonova A, Shilovskiy I, Kozhikhova K, Kofiadi I, ' 'Vishnyakova L, Nikolskii A, Gattinger P, Kovchina V, Barvinskaia E, ' 'Yumashev K, Smirnov V, Maerle A, Kozlov I, Shatilov A, Timofeeva A, ' 'Andreev S, Koloskova O, Kuznetsova N, Vasina D, Nikiforova M, Rybalkin ' 'S, Sergeev I, Trofimov D, Martynov A, Berzin I, Gushchin V, Kovalchuk A, ' 'Borisevich S, Valenta R, Khaitov R, Skvortsova V. Silencing of ' 'SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. Allergy. ' '2021;76(9):2840–54.', 'journal-title': 'Allergy'}, { 'key': '3520_CR34', 'doi-asserted-by': 'publisher', 'first-page': '123', 'DOI': '10.1016/j.cegh.2020.07.011', 'volume': '9', 'author': 'A Frediansyah', 'year': '2021', 'unstructured': 'Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and ' 'its antiviral activity against COVID-19: A systematic review. Clinical ' 'epidemiology and global health. 2021;9:123–7.', 'journal-title': 'Clinical epidemiology and global health'}, { 'issue': '5', 'key': '3520_CR35', 'doi-asserted-by': 'publisher', 'first-page': '1648', 'DOI': '10.1021/acs.jmedchem.6b01594', 'volume': '60', 'author': 'D Siegel', 'year': '2017', 'unstructured': 'Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, ' 'Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, ' 'Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, ' 'Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, ' 'Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL. Discovery and ' 'Synthesis of a Phosphoramidate Prodrug of a ' 'Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the ' 'Treatment of Ebola and Emerging Viruses. J Med Chem. 2017;60(5):1648–61.', 'journal-title': 'J Med Chem'}, { 'issue': '43', 'key': '3520_CR36', 'doi-asserted-by': 'publisher', 'first-page': '26946', 'DOI': '10.1073/pnas.2012294117', 'volume': '117', 'author': 'MK Lo', 'year': '2020', 'unstructured': 'Lo MK, Albariño CG, Perry JK, Chang S, Tchesnokov EP, Guerrero L, ' 'Chakrabarti A, Shrivastava-Ranjan P, Chatterjee P, McMullan LK, Martin ' 'R, Jordan R, Götte M, Montgomery JM, Nichol ST, Flint M, Porter D, ' 'Spiropoulou CF. Remdesivir targets a structurally analogous region of ' 'the Ebola virus and SARS-CoV-2 polymerases. Proc Natl Acad Sci. ' '2020;117(43):26946–54.', 'journal-title': 'Proc Natl Acad Sci'}, { 'issue': '12', 'key': '3520_CR37', 'doi-asserted-by': 'publisher', 'first-page': '6771', 'DOI': '10.1073/pnas.1922083117', 'volume': '117', 'author': 'E de Wit', 'year': '2020', 'unstructured': 'de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, ' 'Cihlar T, Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) ' 'treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl ' 'Acad Sci. 2020;117(12):6771–6.', 'journal-title': 'Proc Natl Acad Sci'}, { 'issue': '7594', 'key': '3520_CR38', 'doi-asserted-by': 'publisher', 'first-page': '381', 'DOI': '10.1038/nature17180', 'volume': '531', 'author': 'TK Warren', 'year': '2016', 'unstructured': 'Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, ' 'Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman ' 'KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, ' 'Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, ' 'Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, ' 'Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang ' 'Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, ' 'Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, ' 'Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, ' 'Cihlar T, Bavari S. Therapeutic efficacy of the small molecule GS-5734 ' 'against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–5.', 'journal-title': 'Nature'}, { 'key': '3520_CR39', 'doi-asserted-by': 'crossref', 'unstructured': 'Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, ' 'Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, ' 'Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar ' 'T, Jordan R, Denison MR, Baric RS. Broad-spectrum antiviral GS-5734 ' 'inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. ' '2017;9(396):eaal3653.', 'DOI': '10.1126/scitranslmed.aal3653'}, { 'key': '3520_CR40', 'first-page': '100073', 'volume': '3', 'author': 'S Sahakijpijarn', 'year': '2021', 'unstructured': 'Sahakijpijarn S, Moon C, Warnken ZN, Maier EY, DeVore JE, Christensen ' 'DJ, Koleng JJ, Williams RO 3rd. In vivo pharmacokinetic study of ' 'remdesivir dry powder for inhalation in hamsters. Int J Pharm X. ' '2021;3:100073.', 'journal-title': 'Int J Pharm X'}, { 'issue': '14', 'key': '3520_CR41', 'doi-asserted-by': 'publisher', 'first-page': '1187', 'DOI': '10.2217/nnm-2020-0475', 'volume': '16', 'author': 'R Vartak', 'year': '2021', 'unstructured': 'Vartak R, Patil SM, Saraswat A, Patki M, Kunda NK, Patel K. Aerosolized ' 'nanoliposomal carrier of remdesivir: an effective alternative for ' 'COVID-19 treatment in vitro. Nanomedicine (Lond). 2021;16(14):1187–202.', 'journal-title': 'Nanomedicine (Lond)'}, { 'issue': '6', 'key': '3520_CR42', 'doi-asserted-by': 'publisher', 'first-page': '772', 'DOI': '10.1016/j.ajps.2021.09.002', 'volume': '16', 'author': 'J Li', 'year': '2021', 'unstructured': 'Li J, Zhang K, Wu D, Ren L, Chu X, Qin C, Han X, Hang T, Xu Y, Yang L, ' 'Yin L. Liposomal remdesivir inhalation solution for targeted lung ' 'delivery as a novel therapeutic approach for COVID-19. Asian J Pharm ' 'Sci. 2021;16(6):772–83.', 'journal-title': 'Asian J Pharm Sci'}, { 'key': '3520_CR43', 'doi-asserted-by': 'publisher', 'first-page': '103625', 'DOI': '10.1016/j.jddst.2022.103625', 'volume': '75', 'author': 'E Halevas', 'year': '2022', 'unstructured': 'Halevas E, Mavroidi B, Kokotidou C, Moschona A, Sagnou M, Mitraki A, ' 'Litsardakis G, Pelecanou M. Remdesivir-loaded bis-MPA hyperbranched ' 'dendritic nanocarriers for pulmonary delivery. J Drug Deliv Sci Technol. ' '2022;75:103625.', 'journal-title': 'J Drug Deliv Sci Technol'}, { 'issue': '4', 'key': '3520_CR44', 'doi-asserted-by': 'publisher', 'first-page': '642', 'DOI': '10.1111/cts.12797', 'volume': '13', 'author': 'SLM Arnold', 'year': '2020', 'unstructured': 'Arnold SLM, Buckner F. Hydroxychloroquine for Treatment of SARS-CoV-2 ' 'Infection? Improving Our Confidence in a Model-Based Approach to Dose ' 'Selection. Clin Transl Sci. 2020;13(4):642–5.', 'journal-title': 'Clin Transl Sci'}, { 'issue': '6', 'key': '3520_CR45', 'doi-asserted-by': 'publisher', 'first-page': '808', 'DOI': '10.1038/s41591-020-0888-2', 'volume': '26', 'author': 'E Chorin', 'year': '2020', 'unstructured': 'Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, Aizer ' 'A, Holmes D, Bernstein S, Spinelli M, Park DS, Chinitz LA, Jankelson L. ' 'The QT interval in patients with COVID-19 treated with ' 'hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808–9.', 'journal-title': 'Nat Med'}, { 'issue': '21', 'key': '3520_CR46', 'doi-asserted-by': 'publisher', 'first-page': '4997', 'DOI': '10.1111/bph.15167', 'volume': '177', 'author': 'SC Fassihi', 'year': '2020', 'unstructured': 'Fassihi SC, Nabar NR, Fassihi R. Novel approach for low-dose pulmonary ' 'delivery of hydroxychloroquine in COVID-19. Br J Pharmacol. ' '2020;177(21):4997–8.', 'journal-title': 'Br J Pharmacol'}, { 'key': '3520_CR47', 'doi-asserted-by': 'publisher', 'first-page': '109783', 'DOI': '10.1016/j.mehy.2020.109783', 'volume': '142', 'author': 'A Klimke', 'year': '2020', 'unstructured': 'Klimke A, Hefner G, Will B, Voss U. Hydroxychloroquine as an aerosol ' 'might markedly reduce and even prevent severe clinical symptoms after ' 'SARS-CoV-2 infection. Med Hypotheses. 2020;142:109783.', 'journal-title': 'Med Hypotheses'}, { 'issue': '1', 'key': '3520_CR48', 'doi-asserted-by': 'publisher', 'first-page': '132', 'DOI': '10.1111/cts.12923', 'volume': '14', 'author': 'TT Tai', 'year': '2021', 'unstructured': 'Tai TT, Wu TJ, Wu HD, Tsai YC, Wang HT, Wang AM, Shih SF, Chen YC. A ' 'Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable ' 'Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study. Clin ' 'Transl Sci. 2021;14(1):132–6.', 'journal-title': 'Clin Transl Sci'}, { 'issue': '1', 'key': '3520_CR49', 'doi-asserted-by': 'publisher', 'first-page': '20', 'DOI': '10.1089/jamp.2020.1648', 'volume': '34', 'author': 'AH Albariqi', 'year': '2020', 'unstructured': 'Albariqi AH, Chang RYK, Tai W, Ke W-R, Chow MYT, Tang P, Kwok PCL, Chan ' 'H-K. Inhalable Hydroxychloroquine Powders for Potential Treatment of ' 'COVID-19. J Aerosol Med Pulm Drug Deliv. 2020;34(1):20–31.', 'journal-title': 'J Aerosol Med Pulm Drug Deliv'}, { 'issue': '8', 'key': '3520_CR50', 'doi-asserted-by': 'publisher', 'first-page': 'e0272034', 'DOI': '10.1371/journal.pone.0272034', 'volume': '17', 'author': 'YA de Reus', 'year': '2022', 'unstructured': 'de Reus YA, Hagedoorn P, Sturkenboom MGG, Grasmeijer F, Bolhuis MS, ' 'Sibum I, Kerstjens HAM, Frijlink HW, Akkerman OW. Tolerability and ' 'pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in ' 'healthy volunteers. PLoS ONE. 2022;17(8):e0272034.', 'journal-title': 'PLoS ONE'}, { 'key': '3520_CR51', 'doi-asserted-by': 'crossref', 'unstructured': 'Ali AS, Alrashedi MG, Ahmed OAA, Ibrahim IM. Pulmonary delivery of ' 'hydroxychloroquine nanostructured lipid carrier as a potential treatment ' 'of COVID-19. Polymers (Basel). 2022;14(13):2616.', 'DOI': '10.3390/polym14132616'}, { 'key': '3520_CR52', 'doi-asserted-by': 'crossref', 'unstructured': 'de Barros AOdS, Pinto SR, dos Reis SRR, Ricci-Junior E, Alencar LMR, ' 'Bellei NCJ, Janini LRM, Maricato JT, Rosa DS, Santos-Oliveira R. ' 'Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded ' 'with azithromycin potentiate anti-SARS-CoV-2 effect. J Nanostruct Chem. ' '2022;13(2):263–81.', 'DOI': '10.1007/s40097-022-00476-3'}, { 'key': '3520_CR53', 'doi-asserted-by': 'crossref', 'unstructured': 'Corritori S, Savchuk N, Pauza CD. Risk/benefit profiles of currently ' 'approved oral antivirals for treatment of COVID-19: similarities and ' 'differences. COVID. 2022;2(8):1057–76.', 'DOI': '10.3390/covid2080078'}, { 'issue': '12', 'key': '3520_CR54', 'doi-asserted-by': 'publisher', 'first-page': 'e0006034', 'DOI': '10.1371/journal.pntd.0006034', 'volume': '11', 'author': 'P Chinello', 'year': '2017', 'unstructured': 'Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E, ' 'on behalf of the IET. QTc interval prolongation during favipiravir ' 'therapy in an Ebolavirus-infected patient. PLOS Negl Trop Dis. ' '2017;11(12):e0006034.', 'journal-title': 'PLOS Negl Trop Dis'}, { 'key': '3520_CR55', 'doi-asserted-by': 'crossref', 'unstructured': 'Akbal-Dagistan O, Sevim M, Sen LS, Basarir NS, Culha M, Erturk A, Fael ' 'H, Kaptan E, Sancar S, Mulazimoglu Durmusoglu L, Yegen BC, Yildiz-Pekoz ' 'A. Pulmonary delivery of favipiravir in rats reaches high local ' 'concentrations without causing oxidative lung injury or systemic side ' 'effects. Pharmaceutics. 2022;14(11):2375.', 'DOI': '10.3390/pharmaceutics14112375'}, { 'issue': '1', 'key': '3520_CR56', 'doi-asserted-by': 'publisher', 'first-page': '2846', 'DOI': '10.1080/10717544.2022.2118398', 'volume': '29', 'author': 'A Yildiz Pekoz', 'year': '2022', 'unstructured': 'Yildiz Pekoz A, Akbal Dagistan O, Fael H, Culha M, Erturk A, Basarir NS, ' 'Sahin G, Serhatli M, Cakirca G, Tekin S, Sen LS, Sevim M, Mulazimoglu ' 'Durmusoglu L, Yegen BC. Pulmonary delivery of favipiravir inhalation ' 'solution for COVID-19 treatment: in vitro characterization, stability, ' 'in vitro cytotoxicity, and antiviral activity using real time cell ' 'analysis. Drug Deliv. 2022;29(1):2846–54.', 'journal-title': 'Drug Deliv'}, { 'issue': '7', 'key': '3520_CR57', 'doi-asserted-by': 'publisher', 'first-page': '3187', 'DOI': '10.1016/j.apsb.2022.01.019', 'volume': '12', 'author': 'B Tu', 'year': '2022', 'unstructured': 'Tu B, Wang H, An X, Qu J, Li Q, Gao Y, Shi M, Qiu H, Huang Y. Inhaled ' 'heparin polysaccharide nanodecoy against SARS-CoV-2 and variants. Acta ' 'Pharm Sin B. 2022;12(7):3187–94.', 'journal-title': 'Acta Pharm Sin B'}, { 'key': '3520_CR58', 'doi-asserted-by': 'publisher', 'first-page': '592238', 'DOI': '10.3389/fphar.2020.592238', 'volume': '11', 'author': 'H Jin', 'year': '2020', 'unstructured': 'Jin H, Zhao Z, Lan Q, Zhou H, Mai Z, Wang Y, Ding X, Zhang W, Pi J, ' 'Evans CE, Liu X. Nasal Delivery of Hesperidin/Chitosan Nanoparticles ' 'Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung ' 'Injury. Front Pharmacol. 2020;11:592238.', 'journal-title': 'Front Pharmacol'}, { 'issue': '6', 'key': '3520_CR59', 'doi-asserted-by': 'publisher', 'first-page': '2059', 'DOI': '10.1016/j.matt.2021.04.005', 'volume': '4', 'author': 'M Chen', 'year': '2021', 'unstructured': 'Chen M, Rosenberg J, Cai X, Lee ACH, Shi J, Nguyen M, Wignakumar T, ' 'Mirle V, Edobor AJ, Fung J, Donington JS, Shanmugarajah K, Lin Y, Chang ' 'E, Randall G, Penaloza-MacMaster P, Tian B, Madariaga ML, Huang J. ' 'Nanotraps for the containment and clearance of SARS-CoV-2. Matter. ' '2021;4(6):2059–82.', 'journal-title': 'Matter'}, { 'issue': '8', 'key': '3520_CR60', 'doi-asserted-by': 'publisher', 'first-page': '942', 'DOI': '10.1038/s41565-021-00923-2', 'volume': '16', 'author': 'Z Li', 'year': '2021', 'unstructured': 'Li Z, Wang Z, Dinh P-UC, Zhu D, Popowski KD, Lutz H, Hu S, Lewis MG, ' 'Cook A, Andersen H, Greenhouse J, Pessaint L, Lobo LJ, Cheng K. ' 'Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury ' 'in a non-human primate model of COVID-19. Nat Nanotechnol. ' '2021;16(8):942–51.', 'journal-title': 'Nat Nanotechnol'}, { 'key': '3520_CR61', 'doi-asserted-by': 'publisher', 'first-page': '121133', 'DOI': '10.1016/j.ijpharm.2021.121133', 'volume': '609', 'author': 'S Ebrahimi', 'year': '2021', 'unstructured': 'Ebrahimi S, Shamloo A, Alishiri M, Mofrad YM, Akherati F. Targeted ' 'pulmonary drug delivery in coronavirus disease (COVID-19) therapy: A ' 'patient-specific in silico study based on magnetic nanoparticles-coated ' 'microcarriers adhesion. Int J Pharm. 2021;609:121133.', 'journal-title': 'Int J Pharm'}, { 'key': '3520_CR62', 'doi-asserted-by': 'publisher', 'first-page': '101', 'DOI': '10.1016/j.ijbiomac.2021.12.073', 'volume': '198', 'author': 'NAN Hanafy', 'year': '2022', 'unstructured': 'Hanafy NAN, El-Kemary MA. Silymarin/curcumin loaded albumin ' 'nanoparticles coated by chitosan as muco-inhalable delivery system ' 'observing anti-inflammatory and anti COVID-19 characterizations in oleic ' 'acid triggered lung injury and in vitro COVID-19 experiment. Int J Biol ' 'Macromol. 2022;198:101–10.', 'journal-title': 'Int J Biol Macromol'}, { 'key': '3520_CR63', 'doi-asserted-by': 'publisher', 'first-page': '117627', 'DOI': '10.1016/j.lfs.2020.117627', 'volume': '251', 'author': 'M Kandeel', 'year': '2020', 'unstructured': 'Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA ' 'approved drugs against COVID-19 main protease. Life Sci. ' '2020;251:117627.', 'journal-title': 'Life Sci'}, { 'issue': '13', 'key': '3520_CR64', 'doi-asserted-by': 'publisher', 'first-page': '2003556', 'DOI': '10.1002/advs.202003556', 'volume': '8', 'author': 'B Li', 'year': '2021', 'unstructured': 'Li B, Wang W, Song W, Zhao Z, Tan Q, Zhao Z, Tang L, Zhu T, Yin J, Bai ' 'J, Dong X, Tan S, Hu Q, Tang BZ, Huang X. Antiviral and ' 'Anti-Inflammatory Treatment with Multifunctional Alveolar ' 'Macrophage-Like Nanoparticles in a Surrogate Mouse Model of COVID-19. ' 'Advanced Science. 2021;8(13):2003556.', 'journal-title': 'Advanced Science'}, { 'key': '3520_CR65', 'doi-asserted-by': 'publisher', 'first-page': '120701', 'DOI': '10.1016/j.ijpharm.2021.120701', 'volume': '603', 'author': 'MO Jara', 'year': '2021', 'unstructured': 'Jara MO, Warnken ZN, Sahakijpijarn S, Moon C, Maier EY, Christensen DJ, ' 'Koleng JJ, Peters JI, Hackman Maier SD, Williams Iii RO. Niclosamide ' 'inhalation powder made by thin-film freezing: Multi-dose tolerability ' 'and exposure in rats and pharmacokinetics in hamsters. Int J Pharm. ' '2021;603:120701.', 'journal-title': 'Int J Pharm'}, { 'key': '3520_CR66', 'doi-asserted-by': 'publisher', 'first-page': '121688', 'DOI': '10.1016/j.ijpharm.2022.121688', 'volume': '619', 'author': 'AH Albariqi', 'year': '2022', 'unstructured': 'Albariqi AH, Wang Y, Chang RYK, Quan DH, Wang X, Kalfas S, Drago J, ' 'Britton WJ, Chan HK. Pharmacokinetics and safety of inhaled ivermectin ' 'in mice as a potential COVID-19 treatment. Int J Pharm. 2022;619:121688.', 'journal-title': 'Int J Pharm'}, { 'issue': '2', 'key': '3520_CR67', 'doi-asserted-by': 'publisher', 'first-page': '510', 'DOI': '10.1016/j.jaci.2020.09.034', 'volume': '147', 'author': 'LJ Finney', 'year': '2021', 'unstructured': 'Finney LJ, Glanville N, Farne H, Aniscenko J, Fenwick P, Kemp SV, ' 'Trujillo-Torralbo MB, Loo SL, Calderazzo MA, Wedzicha JA, Mallia P, ' 'Bartlett NW, Johnston SL, Singanayagam A. Inhaled corticosteroids ' 'downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of ' 'type I interferon. J Allergy Clin Immunol. 2021;147(2):510-519.e515.', 'journal-title': 'J Allergy Clin Immunol'}, { 'key': '3520_CR68', 'doi-asserted-by': 'publisher', 'first-page': '102426', 'DOI': '10.1016/j.plefa.2022.102426', 'volume': '179', 'author': 'C Kocherlakota', 'year': '2022', 'unstructured': 'Kocherlakota C, Nagaraju B, Arjun N, Srinath A, Kothapalli KSD, Brenna ' 'JT. Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced ' 'acute lung inflammation in rats: Implications for treatment of COPD and ' 'COVID-19. Prostaglandins Leukot Essent Fatty Acids. 2022;179:102426.', 'journal-title': 'Prostaglandins Leukot Essent Fatty Acids'}, { 'issue': '7', 'key': '3520_CR69', 'doi-asserted-by': 'publisher', 'first-page': '2100059', 'DOI': '10.1002/adtp.202100059', 'volume': '4', 'author': 'Q Liao', 'year': '2021', 'unstructured': 'Liao Q, Yuan S, Cao J, Tang K, Qiu Y, Seow HC, Man RC-H, Shao Z, Huang ' 'Y, Liang R, Chan JF-W, Yuen K-Y, Lam JK-W. Inhaled Dry Powder ' 'Formulation of Tamibarotene, a Broad-Spectrum Antiviral against ' 'Respiratory Viruses Including SARS-CoV-2 and Influenza Virus. Advanced ' 'Therapeutics. 2021;4(7):2100059.', 'journal-title': 'Advanced Therapeutics'}, { 'key': '3520_CR70', 'doi-asserted-by': 'publisher', 'first-page': '85', 'DOI': '10.1016/j.ejpb.2018.10.008', 'volume': '133', 'author': 'J Tomar', 'year': '2018', 'unstructured': 'Tomar J, Biel C, de Haan CAM, Rottier PJM, Petrovsky N, Frijlink HW, ' 'Huckriede A, Hinrichs WLJ, Peeters B. Passive inhalation of dry powder ' 'influenza vaccine formulations completely protects chickens against H5N1 ' 'lethal viral challenge. Eur J Pharm Biopharm. 2018;133:85–95.', 'journal-title': 'Eur J Pharm Biopharm'}, { 'key': '3520_CR71', 'doi-asserted-by': 'crossref', 'unstructured': 'Aziz S, Scherlieβ R, Steckel H. Development of high dose oseltamivir ' 'phosphate dry powder for inhalation therapy in viral pneumonia. ' 'Pharmaceutics. 2020;12(12):1154.', 'DOI': '10.3390/pharmaceutics12121154'}, { 'issue': '1', 'key': '3520_CR72', 'doi-asserted-by': 'publisher', 'first-page': '59', 'DOI': '10.1038/s41541-021-00320-9', 'volume': '6', 'author': 'JM Luczo', 'year': '2021', 'unstructured': 'Luczo JM, Bousse T, Johnson SK, Jones CA, Pearce N, Neiswanger CA, Wang ' 'M-X, Miller EA, Petrovsky N, Wentworth DE, Bronshtein V, Papania M, ' 'Tompkins SM. Intranasal powder live attenuated influenza vaccine is ' 'thermostable, immunogenic, and protective against homologous challenge ' 'in ferrets. Npj Vaccines. 2021;6(1):59.', 'journal-title': 'Npj Vaccines'}, { 'issue': '8', 'key': '3520_CR73', 'doi-asserted-by': 'publisher', 'first-page': '703', 'DOI': '10.2174/1567201817666200530201820', 'volume': '17', 'author': 'H Sahastrabudhe', 'year': '2020', 'unstructured': 'Sahastrabudhe H, Kenjale P, Pokharkar V. Development of Sustained ' 'Release Oseltamivir Phosphate Dry Powder Inhaler: <i>In-Vitro</i> ' 'Characterization and <i>In-Vivo</i> Toxicological Studies. Curr Drug ' 'Deliv. 2020;17(8):703–10.', 'journal-title': 'Curr Drug Deliv'}, { 'issue': '1', 'key': '3520_CR74', 'doi-asserted-by': 'publisher', 'first-page': '533', 'DOI': '10.1080/10717544.2018.1435748', 'volume': '25', 'author': 'Y Bhide', 'year': '2018', 'unstructured': 'Bhide Y, Tomar J, Dong W, de Vries-Idema J, Frijlink HW, Huckriede A, ' 'Hinrichs WLJ. Pulmonary delivery of influenza vaccine formulations in ' 'cotton rats: site of deposition plays a minor role in the protective ' 'efficacy against clinical isolate of H1N1pdm virus. Drug Deliv. ' '2018;25(1):533–45.', 'journal-title': 'Drug Deliv'}, { 'issue': '52', 'key': '3520_CR75', 'doi-asserted-by': 'publisher', 'first-page': '8707', 'DOI': '10.1016/j.vaccine.2007.10.035', 'volume': '25', 'author': 'JP Amorij', 'year': '2007', 'unstructured': 'Amorij JP, Saluja V, Petersen AH, Hinrichs WL, Huckriede A, Frijlink HW. ' 'Pulmonary delivery of an inulin-stabilized influenza subunit vaccine ' 'prepared by spray-freeze drying induces systemic, mucosal humoral as ' 'well as cell-mediated immune responses in BALB/c mice. Vaccine. ' '2007;25(52):8707–17.', 'journal-title': 'Vaccine'}, { 'issue': '5', 'key': '3520_CR76', 'doi-asserted-by': 'publisher', 'first-page': '608', 'DOI': '10.3109/10717544.2013.863526', 'volume': '22', 'author': 'Y Tang', 'year': '2015', 'unstructured': 'Tang Y, Zhang H, Lu X, Jiang L, Xi X, Liu J, Zhu J. Development and ' 'evaluation of a dry powder formulation of liposome-encapsulated ' 'oseltamivir phosphate for inhalation. Drug Delivery. 2015;22(5):608–18.', 'journal-title': 'Drug Delivery'}, { 'issue': '5', 'key': '3520_CR77', 'doi-asserted-by': 'publisher', 'first-page': '6331', 'DOI': '10.1021/acsami.1c19192', 'volume': '14', 'author': 'C Dong', 'year': '2022', 'unstructured': 'Dong C, Wang Y, Zhu W, Ma Y, Kim J, Wei L, Gonzalez GX, Wang B-Z. ' 'Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza ' 'Immunity in Mice. ACS Appl Mater Interfaces. 2022;14(5):6331–42.', 'journal-title': 'ACS Appl Mater Interfaces'}, { 'issue': '20', 'key': '3520_CR78', 'doi-asserted-by': 'publisher', 'first-page': '2307', 'DOI': '10.1016/j.vaccine.2015.03.063', 'volume': '33', 'author': 'W Tao', 'year': '2015', 'unstructured': 'Tao W, Gill HS. M2e-immobilized gold nanoparticles as influenza A ' 'vaccine: Role of soluble M2e and longevity of protection. Vaccine. ' '2015;33(20):2307–15.', 'journal-title': 'Vaccine'}, { 'issue': '56', 'key': '3520_CR79', 'doi-asserted-by': 'publisher', 'first-page': '35290', 'DOI': '10.1039/C7RA06477B', 'volume': '7', 'author': 'Z Lin', 'year': '2017', 'unstructured': 'Lin Z, Li Y, Guo M, Xiao M, Wang C, Zhao M, Xu T, Xia Y, Zhu B. ' 'Inhibition of H1N1 influenza virus by selenium nanoparticles loaded with ' 'zanamivir through p38 and JNK signaling pathways. RSC Adv. ' '2017;7(56):35290–6.', 'journal-title': 'RSC Adv'}, { 'key': '3520_CR80', 'doi-asserted-by': 'publisher', 'first-page': '102438', 'DOI': '10.1016/j.nano.2021.102438', 'volume': '37', 'author': 'J Lim', 'year': '2021', 'unstructured': 'Lim J, Cheong Y, Kim Y-S, Chae W, Hwang BJ, Lee J, Jang YH, Roh YH, Seo ' 'S-U, Seong BL. RNA-dependent assembly of chimeric antigen nanoparticles ' 'as an efficient H5N1 pre-pandemic vaccine platform. Nanomed: Nanotechnol ' 'Biol Med. 2021;37:102438.', 'journal-title': 'Nanomed: Nanotechnol Biol Med'}, { 'key': '3520_CR81', 'doi-asserted-by': 'publisher', 'first-page': '5733', 'DOI': '10.2147/IJN.S140939', 'volume': '12', 'author': 'Y Li', 'year': '2017', 'unstructured': 'Li Y, Lin Z, Guo M, Xia Y, Zhao M, Wang C, Xu T, Chen T, Zhu B. ' 'Inhibitory activity of selenium nanoparticles functionalized with ' 'oseltamivir on H1N1 influenza virus. Int J Nanomedicine. ' '2017;12:5733–43.', 'journal-title': 'Int J Nanomedicine'}, { 'issue': '2', 'key': '3520_CR82', 'doi-asserted-by': 'publisher', 'first-page': '317', 'DOI': '10.1208/s12249-013-0058-7', 'volume': '15', 'author': 'C Sawaengsak', 'year': '2014', 'unstructured': 'Sawaengsak C, Mori Y, Yamanishi K, Mitrevej A, Sinchaipanid N. Chitosan ' 'nanoparticle encapsulated hemagglutinin-split influenza virus mucosal ' 'vaccine. AAPS PharmSciTech. 2014;15(2):317–25.', 'journal-title': 'AAPS PharmSciTech'}, { 'key': '3520_CR83', 'doi-asserted-by': 'publisher', 'first-page': '934', 'DOI': '10.3389/fimmu.2018.00934', 'volume': '9', 'author': 'S Dhakal', 'year': '2018', 'unstructured': 'Dhakal S, Renu S, Ghimire S, Shaan Lakshmanappa Y, Hogshead BT, ' 'Feliciano-Ruiz N, Lu F, HogenEsch H, Krakowka S, Lee CW, Renukaradhya ' 'GJ. Mucosal Immunity and Protective Efficacy of Intranasal Inactivated ' 'Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs. ' 'Front Immunol. 2018;9:934.', 'journal-title': 'Front Immunol'}, { 'issue': '16', 'key': '3520_CR84', 'doi-asserted-by': 'publisher', 'first-page': 'e0084121', 'DOI': '10.1128/JVI.00841-21', 'volume': '95', 'author': 'SA Nelson', 'year': '2021', 'unstructured': 'Nelson SA, Dileepan T, Rasley A, Jenkins MK, Fischer NO, Sant AJ. ' 'Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional ' 'CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved ' 'Influenza Virus Antigen That Is Sufficient To Mediate Protection from ' 'Influenza Virus Challenge. J Virol. 2021;95(16):e0084121.', 'journal-title': 'J Virol'}, { 'issue': '2', 'key': '3520_CR85', 'doi-asserted-by': 'publisher', 'first-page': '237', 'DOI': '10.2217/nnm.13.58', 'volume': '9', 'author': 'W Tao', 'year': '2014', 'unstructured': 'Tao W, Ziemer KS, Gill HS. Gold nanoparticle-M2e conjugate coformulated ' 'with CpG induces protective immunity against influenza A virus. ' 'Nanomedicine (Lond). 2014;9(2):237–51.', 'journal-title': 'Nanomedicine (Lond)'}, { 'issue': '1', 'key': '3520_CR86', 'doi-asserted-by': 'publisher', 'first-page': '37', 'DOI': '10.1186/s13567-020-00762-4', 'volume': '51', 'author': 'IA Hajam', 'year': '2020', 'unstructured': 'Hajam IA, Senevirathne A, Hewawaduge C, Kim J, Lee JH. Intranasally ' 'administered protein coated chitosan nanoparticles encapsulating ' 'influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity ' 'against avian influenza viruses in chickens. Vet Res. 2020;51(1):37.', 'journal-title': 'Vet Res'}, { 'key': '3520_CR87', 'doi-asserted-by': 'publisher', 'first-page': '777', 'DOI': '10.1016/j.omtn.2020.04.015', 'volume': '20', 'author': 'L Van Hoecke', 'year': '2020', 'unstructured': 'Van Hoecke L, Verbeke R, De Vlieger D, Dewitte H, Roose K, Van Nevel S, ' 'Krysko O, Bachert C, Schepens B, Lentacker I, Saelens X. mRNA Encoding a ' 'Bispecific Single Domain Antibody Construct Protects against Influenza A ' 'Virus Infection in Mice. Mol Therapy Nucleic Acids. 2020;20:777–87.', 'journal-title': 'Mol Therapy Nucleic Acids'}, { 'issue': '9', 'key': '3520_CR88', 'doi-asserted-by': 'publisher', 'first-page': '1059', 'DOI': '10.1038/s41551-021-00786-x', 'volume': '5', 'author': 'MP Lokugamage', 'year': '2021', 'unstructured': 'Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZC, Rotolo L, Echeverri ' 'ES, Peck HE, Ni H, Yoon J-K, Kim Y, Santangelo PJ, Dahlman JE. ' 'Optimization of lipid nanoparticles for the delivery of nebulized ' 'therapeutic mRNA to the lungs. Nat Biomed Eng. 2021;5(9):1059–68.', 'journal-title': 'Nat Biomed Eng'}, { 'issue': '4', 'key': '3520_CR89', 'doi-asserted-by': 'publisher', 'first-page': '1349', 'DOI': '10.1016/j.nano.2018.03.007', 'volume': '14', 'author': 'C Wang', 'year': '2018', 'unstructured': 'Wang C, Zhu W, Luo Y, Wang BZ. Gold nanoparticles conjugating ' 'recombinant influenza hemagglutinin trimers and flagellin enhanced ' 'mucosal cellular immunity. Nanomedicine. 2018;14(4):1349–60.', 'journal-title': 'Nanomedicine'}, { 'key': '3520_CR90', 'doi-asserted-by': 'publisher', 'first-page': '4747', 'DOI': '10.2147/IJN.S137222', 'volume': '12', 'author': 'C Wang', 'year': '2017', 'unstructured': 'Wang C, Zhu W, Wang BZ. Dual-linker gold nanoparticles as adjuvanting ' 'carriers for multivalent display of recombinant influenza hemagglutinin ' 'trimers and flagellin improve the immunological responses in vivo and in ' 'vitro. Int J Nanomedicine. 2017;12:4747–62.', 'journal-title': 'Int J Nanomedicine'}, { 'issue': '12', 'key': '3520_CR91', 'doi-asserted-by': 'publisher', 'first-page': '6221', 'DOI': '10.4049/jimmunol.1202654', 'volume': '190', 'author': 'T Knuschke', 'year': '2013', 'unstructured': 'Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, Staeheli ' 'P, Epple M, Buer J, Westendorf AM. Immunization with biodegradable ' 'nanoparticles efficiently induces cellular immunity and protects against ' 'influenza virus infection. J Immunol. 2013;190(12):6221–9.', 'journal-title': 'J Immunol'}, { 'issue': '8', 'key': '3520_CR92', 'doi-asserted-by': 'publisher', 'first-page': '2395', 'DOI': '10.1016/j.nano.2017.08.001', 'volume': '13', 'author': 'A Frede', 'year': '2017', 'unstructured': 'Frede A, Neuhaus B, Knuschke T, Wadwa M, Kollenda S, Klopfleisch R, ' 'Hansen W, Buer J, Bruder D, Epple M, Westendorf AM. Local delivery of ' 'siRNA-loaded calcium phosphate nanoparticles abates pulmonary ' 'inflammation. Nanomedicine. 2017;13(8):2395–403.', 'journal-title': 'Nanomedicine'}, { 'issue': '1', 'key': '3520_CR93', 'doi-asserted-by': 'publisher', 'first-page': '12', 'DOI': '10.1007/s13346-017-0426-z', 'volume': '8', 'author': 'A Jamali', 'year': '2018', 'unstructured': 'Jamali A, Mottaghitalab F, Abdoli A, Dinarvand M, Esmailie A, Kheiri MT, ' 'Atyabi F. Inhibiting influenza virus replication and inducing protection ' 'against lethal influenza virus challenge through chitosan nanoparticles ' 'loaded by siRNA. Drug Deliv Transl Res. 2018;8(1):12–20.', 'journal-title': 'Drug Deliv Transl Res'}, { 'issue': '26', 'key': '3520_CR94', 'doi-asserted-by': 'publisher', 'first-page': '4345', 'DOI': '10.1016/j.vaccine.2011.04.029', 'volume': '29', 'author': 'SA Audouy', 'year': '2011', 'unstructured': 'Audouy SA, van der Schaaf G, Hinrichs WL, Frijlink HW, Wilschut J, ' 'Huckriede A. Development of a dried influenza whole inactivated virus ' 'vaccine for pulmonary immunization. Vaccine. 2011;29(26):4345–52.', 'journal-title': 'Vaccine'}, { 'key': '3520_CR95', 'doi-asserted-by': 'publisher', 'first-page': '51', 'DOI': '10.1016/j.jconrel.2013.11.013', 'volume': '174', 'author': 'HP Patil', 'year': '2014', 'unstructured': 'Patil HP, Murugappan S, ter Veer W, Meijerhof T, de Haan A, Frijlink HW, ' 'Wilschut J, Hinrichs WL, Huckriede A. Evaluation of monophosphoryl lipid ' 'A as adjuvant for pulmonary delivered influenza vaccine. J Control ' 'Release. 2014;174:51–62.', 'journal-title': 'J Control Release'}, { 'issue': '1', 'key': '3520_CR96', 'doi-asserted-by': 'publisher', 'first-page': 'e2', 'DOI': '10.1016/S1473-3099(22)00291-2', 'volume': '23', 'author': 'NI Mazur', 'year': '2023', 'unstructured': 'Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, ' 'Cohen C, Crowe JE, Cutland CL, Eckert L, Feikin D, Fitzpatrick T, Fong ' 'Y, Graham BS, Heikkinen T, Higgins D, Hirve S, Klugman KP, ' 'Kragten-Tabatabaie L, Lemey P, Libster R, Löwensteyn Y, Mejias A, Munoz ' 'FM, Munywoki PK, Mwananyanda L, Nair H, Nunes MC, Ramilo O, Richmond P, ' 'Ruckwardt TJ, Sande C, Srikantiah P, Thacker N, Waldstein KA, Weinberger ' 'D, Wildenbeest J, Wiseman D, Zar HJ, Zambon M, Bont L. Respiratory ' 'syncytial virus prevention within reach: the vaccine and monoclonal ' 'antibody landscape. Lancet Infect Dis. 2023;23(1):e2–21.', 'journal-title': 'Lancet Infect Dis'}, { 'key': '3520_CR97', 'doi-asserted-by': 'publisher', 'first-page': '34108', 'DOI': '10.1038/srep34108', 'volume': '6', 'author': 'AM Killikelly', 'year': '2016', 'unstructured': 'Killikelly AM, Kanekiyo M, Graham BS. Pre-fusion F is absent on the ' 'surface of formalin-inactivated respiratory syncytial virus. Sci Rep. ' '2016;6:34108.', 'journal-title': 'Sci Rep'}, { 'issue': '3', 'key': '3520_CR98', 'doi-asserted-by': 'publisher', 'first-page': 'e1004757', 'DOI': '10.1371/journal.ppat.1004757', 'volume': '11', 'author': 'CJ Knudson', 'year': '2015', 'unstructured': 'Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM. RSV Vaccine-Enhanced ' 'Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell ' 'Subsets. PLoS Pathog. 2015;11(3):e1004757.', 'journal-title': 'PLoS Pathog'}, { 'issue': '4', 'key': '3520_CR99', 'doi-asserted-by': 'publisher', 'first-page': '672', 'DOI': '10.3390/vaccines8040672', 'volume': '8', 'author': 'C Biagi', 'year': '2020', 'unstructured': 'Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G, Lanari M. ' 'Current state and challenges in developing respiratory syncytial virus ' 'vaccines. Vaccines. 2020;8(4):672.', 'journal-title': 'Vaccines.'}, { 'issue': '2', 'key': '3520_CR100', 'doi-asserted-by': 'publisher', 'first-page': 'e0228572', 'DOI': '10.1371/journal.pone.0228572', 'volume': '15', 'author': 'X Liu', 'year': '2020', 'unstructured': 'Liu X, Liang B, Liu X, Amaro-Carambot E, Surman S, Kwong PD, Graham BS, ' 'Collins PL, Munir S. Human parainfluenza virus type 3 expressing the ' 'respiratory syncytial virus pre-fusion F protein modified for virion ' 'packaging yields protective intranasal vaccine candidates. PLoS ONE. ' '2020;15(2):e0228572.', 'journal-title': 'PLoS ONE'}, { 'issue': '2', 'key': '3520_CR101', 'doi-asserted-by': 'publisher', 'first-page': '554', 'DOI': '10.1080/21645515.2020.1779517', 'volume': '17', 'author': 'F Scaggs Huang', 'year': '2021', 'unstructured': 'Scaggs Huang F, Bernstein DI, Slobod KS, Portner A, Takimoto T, Russell ' 'CJ, Meagher M, Jones BG, Sealy RE, Coleclough C, Branum K, Dickey M, ' 'Buschle K, McNeal M, Makowski M, Nakamura A, Hurwitz JL. Safety and ' 'immunogenicity of an intranasal sendai virus-based vaccine for human ' 'parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in ' 'adults. Hum Vaccin Immunother. 2021;17(2):554–9.', 'journal-title': 'Hum Vaccin Immunother'}, { 'issue': '4', 'key': '3520_CR102', 'doi-asserted-by': 'publisher', 'first-page': '224', 'DOI': '10.1177/0018578719836646', 'volume': '55', 'author': 'L Avery', 'year': '2020', 'unstructured': 'Avery L, Hoffmann C, Whalen KM. The Use of Aerosolized Ribavirin in ' 'Respiratory Syncytial Virus Lower Respiratory Tract Infections in Adult ' 'Immunocompromised Patients: A Systematic Review. Hosp Pharm. ' '2020;55(4):224–35.', 'journal-title': 'Hosp Pharm'}, { 'issue': '10', 'key': '3520_CR103', 'doi-asserted-by': 'publisher', 'first-page': '1641', 'DOI': '10.1093/cid/ciy760', 'volume': '68', 'author': 'F Foolad', 'year': '2019', 'unstructured': 'Foolad F, Aitken SL, Shigle TL, Prayag A, Ghantoji S, Ariza-Heredia E, ' 'Chemaly RF. Oral Versus Aerosolized Ribavirin for the Treatment of ' 'Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant ' 'Recipients. Clin Infect Dis. 2019;68(10):1641–9.', 'journal-title': 'Clin Infect Dis'}, { 'issue': '2', 'key': '3520_CR104', 'doi-asserted-by': 'publisher', 'first-page': 'e12844', 'DOI': '10.1111/tid.12844', 'volume': '20', 'author': 'TP Trang', 'year': '2018', 'unstructured': 'Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative ' 'effectiveness of aerosolized versus oral ribavirin for the treatment of ' 'respiratory syncytial virus infections: A single-center retrospective ' 'cohort study and review of the literature. Transpl Infect Dis. ' '2018;20(2):e12844.', 'journal-title': 'Transpl Infect Dis'}, { 'issue': '8', 'key': '3520_CR105', 'doi-asserted-by': 'publisher', 'first-page': '1872', 'DOI': '10.1093/jac/dkt111', 'volume': '68', 'author': 'DP Shah', 'year': '2013', 'unstructured': 'Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, ' 'Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. Impact of aerosolized ' 'ribavirin on mortality in 280 allogeneic haematopoietic stem cell ' 'transplant recipients with respiratory syncytial virus infections. J ' 'Antimicrob Chemother. 2013;68(8):1872–80.', 'journal-title': 'J Antimicrob Chemother'}, { 'issue': '10', 'key': '3520_CR106', 'doi-asserted-by': 'publisher', 'first-page': '1621', 'DOI': '10.1093/infdis/jit071', 'volume': '207', 'author': 'G Fatkenheuer', 'year': '2013', 'unstructured': 'Fatkenheuer G, Gillor D, Platten M, Kochanek M, Salzberger B. ' 'Aerosolized ribavirin for patients with cancer and respiratory syncytial ' 'virus infection. J Infect Dis. 2013;207(10):1621.', 'journal-title': 'J Infect Dis'}, { 'issue': '9', 'key': '3520_CR107', 'doi-asserted-by': 'publisher', 'first-page': '1367', 'DOI': '10.1093/infdis/jis516', 'volume': '206', 'author': 'RF Chemaly', 'year': '2012', 'unstructured': 'Chemaly RF, Torres HA, Munsell MF, Shah DP, Rathod DB, Bodey GP, Hosing ' 'C, Saifan C, Raad II, Champlin RE. An adaptive randomized trial of an ' 'intermittent dosing schedule of aerosolized ribavirin in patients with ' 'cancer and respiratory syncytial virus infection. J Infect Dis. ' '2012;206(9):1367–71.', 'journal-title': 'J Infect Dis'}, { 'issue': '7', 'key': '3520_CR108', 'doi-asserted-by': 'publisher', 'first-page': '490', 'DOI': '10.1007/s11908-015-0490-9', 'volume': '17', 'author': 'K Neemann', 'year': '2015', 'unstructured': 'Neemann K, Freifeld A. Respiratory Syncytial Virus in Hematopoietic Stem ' 'Cell Transplantation and Solid-Organ Transplantation. Curr Infect Dis ' 'Rep. 2015;17(7):490.', 'journal-title': 'Curr Infect Dis Rep'}, { 'issue': '10', 'key': '3520_CR109', 'doi-asserted-by': 'publisher', 'first-page': '2755', 'DOI': '10.1182/blood-2010-08-263400', 'volume': '117', 'author': 'JN Shah', 'year': '2011', 'unstructured': 'Shah JN, Chemaly RF. Management of RSV infections in adult recipients of ' 'hematopoietic stem cell transplantation. Blood. 2011;117(10):2755–63.', 'journal-title': 'Blood'}, { 'issue': '1', 'key': '3520_CR110', 'doi-asserted-by': 'publisher', 'first-page': '6', 'DOI': '10.1128/AAC.01802-15', 'volume': '60', 'author': 'L Detalle', 'year': '2016', 'unstructured': 'Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, ' 'Power UF, Stortelers C, Allosery K, Melero JA, Depla E. Generation and ' 'Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for ' 'the Treatment of Respiratory Syncytial Virus Infection. Antimicrob ' 'Agents Chemother. 2016;60(1):6–13.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '5', 'key': '3520_CR111', 'doi-asserted-by': 'publisher', 'first-page': '778', 'DOI': '10.1080/19420862.2018.1470727', 'volume': '10', 'author': 'A Larios Mora', 'year': '2018', 'unstructured': 'Larios Mora A, Detalle L, Gallup JM, Van Geelen A, Stohr T, Duprez L, ' 'Ackermann MR. Delivery of ALX-0171 by inhalation greatly reduces ' 'respiratory syncytial virus disease in newborn lambs. MAbs. ' '2018;10(5):778–95.', 'journal-title': 'MAbs'}, { 'issue': '1', 'key': '3520_CR112', 'doi-asserted-by': 'publisher', 'first-page': '21', 'DOI': '10.1016/S2213-2600(20)30320-9', 'volume': '9', 'author': 'S Cunningham', 'year': '2021', 'unstructured': 'Cunningham S, Piedra PA, Martinon-Torres F, Szymanski H, Brackeva B, ' 'Dombrecht E, Detalle L, Fleurinck C. Nebulised ALX-0171 for respiratory ' 'syncytial virus lower respiratory tract infection in hospitalised ' 'children: a double-blind, randomised, placebo-controlled, phase 2b ' 'trial. Lancet Respir Med. 2021;9(1):21–32.', 'journal-title': 'Lancet Respir Med'}, { 'issue': '7', 'key': '3520_CR113', 'doi-asserted-by': 'publisher', 'first-page': 'e21823', 'DOI': '10.1371/journal.pone.0021823', 'volume': '6', 'author': 'DM Lindell', 'year': '2011', 'unstructured': 'Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, Baker ' 'JR Jr, Lukacs NW. A novel inactivated intranasal respiratory syncytial ' 'virus vaccine promotes viral clearance without Th2 associated ' 'vaccine-enhanced disease. PLoS ONE. 2011;6(7):e21823.', 'journal-title': 'PLoS ONE'}, { 'issue': '12', 'key': '3520_CR114', 'doi-asserted-by': 'publisher', 'first-page': '2904', 'DOI': '10.1080/21645515.2015.1075680', 'volume': '11', 'author': "JJ O'Konek", 'year': '2015', 'unstructured': 'O’Konek JJ, Makidon PE, Landers JJ, Cao Z, Malinczak CA, Pannu J, Sun J, ' 'Bitko V, Ciotti S, Hamouda T, Wojcinski ZW, Lukacs NW, Fattom A, Baker ' 'JR Jr. Intranasal nanoemulsion-based inactivated respiratory syncytial ' 'virus vaccines protect against viral challenge in cotton rats. Hum ' 'Vaccin Immunother. 2015;11(12):2904–12.', 'journal-title': 'Hum Vaccin Immunother'}, { 'issue': '2', 'key': '3520_CR115', 'doi-asserted-by': 'publisher', 'first-page': '798', 'DOI': '10.3390/v7020798', 'volume': '7', 'author': 'Z Sun', 'year': '2015', 'unstructured': 'Sun Z, Wang Q, Jia R, Xia S, Li Y, Liu Q, Xu W, Xu J, Du L, Lu L, Jiang ' 'S. Intranasal administration of maleic anhydride-modified human serum ' 'albumin for pre-exposure prophylaxis of respiratory syncytial virus ' 'infection. Viruses. 2015;7(2):798–819.', 'journal-title': 'Viruses'}, { 'issue': '30', 'key': '3520_CR116', 'doi-asserted-by': 'publisher', 'first-page': '4063', 'DOI': '10.1016/j.vaccine.2021.06.013', 'volume': '39', 'author': 'V Ivanov', 'year': '2021', 'unstructured': 'Ivanov V, Oomens AGP, Papin JF, Staats R, Reuter DN, Yu Z, Piedra PA, ' 'Wellliver RC Sr. Intranasal and intrapulmonary vaccination with an M ' 'protein-deficient respiratory syncytial virus (RSV) vaccine improves ' 'clinical signs and reduces viral replication in infant baboons after an ' 'RSV challenge infection. Vaccine. 2021;39(30):4063–71.', 'journal-title': 'Vaccine'}, { 'key': '3520_CR117', 'doi-asserted-by': 'publisher', 'first-page': '57', 'DOI': '10.1016/j.antiviral.2017.05.005', 'volume': '144', 'author': 'YY Jiao', 'year': '2017', 'unstructured': 'Jiao YY, Fu YH, Yan YF, Hua Y, Ma Y, Zhang XJ, Song JD, Peng XL, Huang ' 'J, Hong T, He JS. A single intranasal administration of virus-like ' 'particle vaccine induces an efficient protection for mice against human ' 'respiratory syncytial virus. Antiviral Res. 2017;144:57–69.', 'journal-title': 'Antiviral Res'}, { 'issue': '1', 'key': '3520_CR118', 'doi-asserted-by': 'publisher', 'first-page': '74', 'DOI': '10.1093/abbs/gmw118', 'volume': '49', 'author': 'M Cai', 'year': '2017', 'unstructured': 'Cai M, Wang C, Li Y, Gu H, Sun S, Duan Y, Lai C, Wang K, Yang X, Xing L, ' 'Zhang P, Wang Z, Zhang S, Guo X, Liu S, Tong Y, Wang X, Yang P. ' 'Virus-like particle vaccine by intranasal vaccination elicits protective ' 'immunity against respiratory syncytial viral infection in mice. Acta ' 'Biochim Biophys Sin (Shanghai). 2017;49(1):74–82.', 'journal-title': 'Acta Biochim Biophys Sin (Shanghai)'}, { 'key': '3520_CR119', 'doi-asserted-by': 'crossref', 'unstructured': 'Garg R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. ' 'Intranasal immunization with a single dose of the fusion protein ' 'formulated with a combination adjuvant induces long-term protective ' 'immunity against respiratory syncytial virus. Hum Vaccin Immunother. ' '2017;13(12):2894–901.', 'DOI': '10.1080/21645515.2017.1349584'}, { 'key': '3520_CR120', 'doi-asserted-by': 'crossref', 'unstructured': 'Garg R, Theaker M, Martinez EC, van Drunen Littel-van den Hurk S. A ' 'single intranasal immunization with a subunit vaccine formulation ' 'induces higher mucosal IgA production than live respiratory syncytial ' 'virus. Virology. 2016;499:288–97.', 'DOI': '10.1016/j.virol.2016.09.023'}, { 'issue': '2', 'key': '3520_CR121', 'doi-asserted-by': 'publisher', 'first-page': '189', 'DOI': '10.1586/14760584.2016.1114418', 'volume': '15', 'author': 'CJ Russell', 'year': '2016', 'unstructured': 'Russell CJ, Hurwitz JL. Sendai virus as a backbone for vaccines against ' 'RSV and other human paramyxoviruses. Expert Rev Vaccines. ' '2016;15(2):189–200.', 'journal-title': 'Expert Rev Vaccines'}, { 'issue': '1', 'key': '3520_CR122', 'doi-asserted-by': 'publisher', 'first-page': '34', 'DOI': '10.1016/j.jpeds.2007.02.032', 'volume': '151', 'author': 'EA Simoes', 'year': '2007', 'unstructured': 'Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, ' 'Fredrick LM, Kimpen JL. Palivizumab prophylaxis, respiratory syncytial ' 'virus, and subsequent recurrent wheezing. J Pediatr. 2007;151(1):34–42, ' '42 e31.', 'journal-title': 'J Pediatr'}, { 'issue': '26', 'key': '3520_CR123', 'doi-asserted-by': 'publisher', 'first-page': '3264', 'DOI': '10.1016/j.vaccine.2014.03.088', 'volume': '32', 'author': 'BG Jones', 'year': '2014', 'unstructured': 'Jones BG, Sealy RE, Surman SL, Portner A, Russell CJ, Slobod KS, ' 'Dormitzer PR, DeVincenzo J, Hurwitz JL. Sendai virus-based RSV vaccine ' 'protects against RSV challenge in an in vivo maternal antibody model. ' 'Vaccine. 2014;32(26):3264–73.', 'journal-title': 'Vaccine'}, { 'issue': '5', 'key': '3520_CR124', 'doi-asserted-by': 'publisher', 'first-page': '959', 'DOI': '10.1016/j.vaccine.2011.11.046', 'volume': '30', 'author': 'BG Jones', 'year': '2012', 'unstructured': 'Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, ' 'Takimoto T, Portner A, Hurwitz JL. Sendai virus-based RSV vaccine ' 'protects African green monkeys from RSV infection. Vaccine. ' '2012;30(5):959–68.', 'journal-title': 'Vaccine'}, { 'issue': '24', 'key': '3520_CR125', 'doi-asserted-by': 'publisher', 'first-page': '11626', 'DOI': '10.1128/JVI.74.24.11626-11635.2000', 'volume': '74', 'author': 'AA Haller', 'year': '2000', 'unstructured': 'Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface ' 'glycoproteins of human parainfluenza virus type 3 by bovine ' 'parainfluenza virus type 3, a novel attenuated virus vaccine vector. J ' 'Virol. 2000;74(24):11626–35.', 'journal-title': 'J Virol'}, { 'issue': '7', 'key': '3520_CR126', 'doi-asserted-by': 'publisher', 'first-page': '655', 'DOI': '10.1097/INF.0b013e318199c3b1', 'volume': '28', 'author': 'M Gomez', 'year': '2009', 'unstructured': 'Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I ' 'study MEDI-534, of a live, attenuated intranasal vaccine against ' 'respiratory syncytial virus and parainfluenza-3 virus in seropositive ' 'children. Pediatr Infect Dis J. 2009;28(7):655–8.', 'journal-title': 'Pediatr Infect Dis J'}, { 'issue': '2', 'key': '3520_CR127', 'doi-asserted-by': 'publisher', 'first-page': '109', 'DOI': '10.1097/INF.0b013e31823386f1', 'volume': '31', 'author': 'DI Bernstein', 'year': '2012', 'unstructured': 'Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. Phase 1 ' 'study of the safety and immunogenicity of a live, attenuated respiratory ' 'syncytial virus and parainfluenza virus type 3 vaccine in seronegative ' 'children. Pediatr Infect Dis J. 2012;31(2):109–14.', 'journal-title': 'Pediatr Infect Dis J'}, { 'issue': '36', 'key': '3520_CR128', 'doi-asserted-by': 'publisher', 'first-page': '3756', 'DOI': '10.1016/j.vaccine.2013.04.015', 'volume': '31', 'author': 'CL Nelson', 'year': '2013', 'unstructured': 'Nelson CL, Tang RS, Stillman EA. Genetic stability of RSV-F expression ' 'and the restricted growth phenotype of a live attenuated PIV3 vectored ' 'RSV vaccine candidate (MEDI-534) following restrictive growth in human ' 'lung cells. Vaccine. 2013;31(36):3756–62.', 'journal-title': 'Vaccine'}, { 'key': '3520_CR129', 'doi-asserted-by': 'crossref', 'first-page': '282', 'DOI': '10.3389/fimmu.2013.00282', 'volume': '4', 'author': 'N Van Braeckel-Budimir', 'year': '2013', 'unstructured': 'Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. Bacterium-like ' 'particles for efficient immune stimulation of existing vaccines and new ' 'subunit vaccines in mucosal applications. Front Immunol. 2013;4:282.', 'journal-title': 'Front Immunol'}, { 'issue': '4', 'key': '3520_CR130', 'doi-asserted-by': 'publisher', 'first-page': '481', 'DOI': '10.1164/rccm.201810-1921OC', 'volume': '200', 'author': 'S Ascough', 'year': '2019', 'unstructured': 'Ascough S, Vlachantoni I, Kalyan M, Haijema BJ, Wallin-Weber S, ' 'Dijkstra-Tiekstra M, Ahmed MS, van Roosmalen M, Grimaldi R, Zhang Q, ' 'Leenhouts K, Openshaw PJ, Chiu C. Local and Systemic Immunity against ' 'Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A ' 'Randomized, Double-Blind, Placebo-controlled Clinical Trial. Am J Respir ' 'Crit Care Med. 2019;200(4):481–92.', 'journal-title': 'Am J Respir Crit Care Med'}, { 'issue': '2', 'key': '3520_CR131', 'doi-asserted-by': 'publisher', 'first-page': '213', 'DOI': '10.1016/j.healun.2015.08.012', 'volume': '35', 'author': 'J Gottlieb', 'year': '2016', 'unstructured': 'Gottlieb J, Zamora MR, Hodges T, Musk AW, Sommerwerk U, Dilling D, ' 'Arcasoy S, DeVincenzo J, Karsten V, Shah S, Bettencourt BR, Cehelsky J, ' 'Nochur S, Gollob J, Vaishnaw A, Simon AR, Glanville AR. ALN-RSV01 for ' 'prevention of bronchiolitis obliterans syndrome after respiratory ' 'syncytial virus infection in lung transplant recipients. J Heart Lung ' 'Transplant. 2016;35(2):213–21.', 'journal-title': 'J Heart Lung Transplant'}, { 'issue': '3', 'key': '3520_CR132', 'doi-asserted-by': 'publisher', 'first-page': '225', 'DOI': '10.1016/j.antiviral.2007.11.009', 'volume': '77', 'author': 'J DeVincenzo', 'year': '2008', 'unstructured': 'DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska ' 'I, Nechev L, Murugaiah V, Van Vliet A, Vaishnaw AK, Meyers R. Evaluation ' 'of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel ' 'RNAi antiviral therapeutic directed against respiratory syncytial virus ' '(RSV). Antiviral Res. 2008;77(3):225–31.', 'journal-title': 'Antiviral Res'}, { 'issue': '4', 'key': '3520_CR133', 'doi-asserted-by': 'publisher', 'first-page': '531', 'DOI': '10.1164/rccm.201003-0422OC', 'volume': '183', 'author': 'MR Zamora', 'year': '2011', 'unstructured': 'Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, DeVincenzo J, Vaishnaw ' 'A, Cehelsky J, Albert G, Nochur S, Gollob JA, Glanville AR. RNA ' 'Interference Therapy in Lung Transplant Patients Infected with ' 'Respiratory Syncytial Virus. Am J Respir Crit Care Med. ' '2011;183(4):531–8.', 'journal-title': 'Am J Respir Crit Care Med'}, { 'issue': '1', 'key': '3520_CR134', 'doi-asserted-by': 'publisher', 'first-page': '82', 'DOI': '10.1093/infdis/jiz408', 'volume': '222', 'author': 'RA Karron', 'year': '2020', 'unstructured': 'Karron RA, Luongo C, Mateo JS, Wanionek K, Collins PL, Buchholz UJ. ' 'Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine ' 'RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children. J Infect Dis. ' '2020;222(1):82–91.', 'journal-title': 'J Infect Dis'}, { 'issue': '9', 'key': '3520_CR135', 'doi-asserted-by': 'publisher', 'first-page': '1347', 'DOI': '10.1093/infdis/jiy040', 'volume': '217', 'author': 'EJ McFarland', 'year': '2018', 'unstructured': 'McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, ' 'Perlowski C, Thumar B, Gnanashanmugam D, Siberry GK, Schappell E, Barr ' 'E, Rexroad V, Yogev R, Spector SA, Aziz M, Patel N, Cielo M, Luongo C, ' 'Collins PL, Buchholz UJ. Live-Attenuated Respiratory Syncytial Virus ' 'Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2–2 ' 'is Highly Immunogenic in Children. J Infect Dis. 2018;217(9):1347–55.', 'journal-title': 'J Infect Dis'}, { 'issue': '4', 'key': '3520_CR136', 'doi-asserted-by': 'publisher', 'first-page': '534', 'DOI': '10.1093/infdis/jiz603', 'volume': '221', 'author': 'EJ McFarland', 'year': '2020', 'unstructured': 'McFarland EJ, Karron RA, Muresan P, Cunningham CK, Libous J, Perlowski ' 'C, Thumar B, Gnanashanmugam D, Moye J, Schappell E, Barr E, Rexroad V, ' 'Fearn L, Spector SA, Aziz M, Cielo M, Beneri C, Wiznia A, Luongo C, ' 'Collins P, Buchholz UJ. Live Respiratory Syncytial Virus Attenuated by ' 'M2–2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a ' 'Promising Vaccine Candidate in Children. J Infect Dis. ' '2020;221(4):534–43.', 'journal-title': 'J Infect Dis'}, { 'issue': '9', 'key': '3520_CR137', 'doi-asserted-by': 'publisher', 'first-page': '1338', 'DOI': '10.1093/infdis/jiy066', 'volume': '217', 'author': 'UJ Buchholz', 'year': '2018', 'unstructured': 'Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, Siberry ' 'GK, Rexroad V, Valentine M, Perlowski C, Schappell E, Thumar B, Luongo ' 'C, Barr E, Aziz M, Yogev R, Spector SA, Collins PL, McFarland EJ, Karron ' 'RA, International Maternal Pediatric Adolescent ACTPST. Live Respiratory ' 'Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized ' 'Temperature-Sensitivity Mutations Is Highly Attenuated in ' 'RSV-Seronegative Infants and Children. J Infect Dis. ' '2018;217(9):1338–46.', 'journal-title': 'J Infect Dis'}, { 'issue': '312', 'key': '3520_CR138', 'doi-asserted-by': 'publisher', 'first-page': '312ra175', 'DOI': '10.1126/scitranslmed.aac8463', 'volume': '7', 'author': 'RA Karron', 'year': '2015', 'unstructured': 'Karron RA, Luongo C, Thumar B, Loehr KM, Englund JA, Collins PL, ' 'Buchholz UJ. A gene deletion that up-regulates viral gene expression ' 'yields an attenuated RSV vaccine with improved antibody responses in ' 'children. Sci Trans Med. 2015;7(312):312ra175.', 'journal-title': 'Sci Trans Med'}, { 'issue': '12', 'key': '3520_CR139', 'doi-asserted-by': 'publisher', 'first-page': '2050', 'DOI': '10.1093/infdis/jiaa049', 'volume': '221', 'author': 'EJ McFarland', 'year': '2020', 'unstructured': 'McFarland EJ, Karron RA, Muresan P, Cunningham CK, Perlowski C, Libous ' 'J, Oliva J, Jean-Philippe P, Moye J, Schappell E, Barr E, Rexroad V, ' 'Fearn L, Cielo M, Wiznia A, Deville JG, Yang L, Luongo C, Collins PL, ' 'Buchholz UJ. Live-Attenuated Respiratory Syncytial Virus Vaccine With ' 'M2–2 Deletion and With Small Hydrophobic Noncoding Region Is Highly ' 'Immunogenic in Children. J Infect Dis. 2020;221(12):2050–9.', 'journal-title': 'J Infect Dis'}, { 'issue': '10', 'key': '3520_CR140', 'doi-asserted-by': 'publisher', 'first-page': 'e008748', 'DOI': '10.1136/bmjopen-2015-008748', 'volume': '5', 'author': 'CA Green', 'year': '2015', 'unstructured': 'Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, Cortese ' 'R, Thompson AJ, Sande CS, de Lara C, Klenerman P, Pollard AJ. Safety and ' 'immunogenicity of novel respiratory syncytial virus (RSV) vaccines based ' 'on the RSV viral proteins F, N and M2–1 encoded by simian adenovirus ' '(PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, ' 'dose-escalation, single-centre, phase 1 clinical trial in healthy ' 'adults. BMJ Open. 2015;5(10):e008748.', 'journal-title': 'BMJ Open'}, { 'issue': '300', 'key': '3520_CR141', 'doi-asserted-by': 'publisher', 'first-page': '300ra126', 'DOI': '10.1126/scitranslmed.aac5745', 'volume': '7', 'author': 'CA Green', 'year': '2015', 'unstructured': 'Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, ' 'Haworth K, Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori ' 'A, Colloca S, Capone S, Vitelli A, Cortese R, Klenerman P, Nicosia A, ' 'Pollard AJ. Chimpanzee adenovirus- and MVA-vectored respiratory ' 'syncytial virus vaccine is safe and immunogenic in adults. Sci Trans ' 'Med. 2015;7(300):300ra126.', 'journal-title': 'Sci Trans Med'}, { 'issue': '5', 'key': '3520_CR142', 'doi-asserted-by': 'publisher', 'first-page': '382', 'DOI': '10.1016/j.jinf.2019.02.003', 'volume': '78', 'author': 'CA Green', 'year': '2019', 'unstructured': 'Green CA, Sande CJ, Scarselli E, Capone S, Vitelli A, Nicosia A, ' 'Silva-Reyes L, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Hutchings ' 'CL, Cargill T, Angus B, Klenerman P, Pollard AJ. Novel ' 'genetically-modified chimpanzee adenovirus and MVA-vectored respiratory ' 'syncytial virus vaccine safely boosts humoral and cellular immunity in ' 'healthy older adults. J Infect. 2019;78(5):382–92.', 'journal-title': 'J Infect'}, { 'issue': '1', 'key': '3520_CR143', 'doi-asserted-by': 'publisher', 'first-page': '130', 'DOI': '10.1124/dmd.122.000934', 'volume': '51', 'author': 'ER McColl', 'year': '2023', 'unstructured': 'McColl ER, Croyle MA, Zamboni WC, Honer WG, Heise M, Piquette-Miller M, ' 'Goralski KB. COVID-19 Vaccines and the Virus: Impact on Drug Metabolism ' 'and Pharmacokinetics. Drug Metab Dispos. 2023;51(1):130–41.', 'journal-title': 'Drug Metab Dispos'}], 'container-title': 'Pharmaceutical Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11095-023-03520-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s11095-023-03520-1/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11095-023-03520-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 4, 25]], 'date-time': '2023-04-25T21:03:05Z', 'timestamp': 1682456585000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s11095-023-03520-1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 4, 25]]}, 'references-count': 143, 'alternative-id': ['3520'], 'URL': 'http://dx.doi.org/10.1007/s11095-023-03520-1', 'relation': {}, 'ISSN': ['0724-8741', '1573-904X'], 'subject': [ 'Pharmacology (medical)', 'Organic Chemistry', 'Pharmaceutical Science', 'Pharmacology', 'Molecular Medicine', 'Biotechnology'], 'container-title-short': 'Pharm Res', 'published': {'date-parts': [[2023, 4, 25]]}, 'assertion': [ { 'value': '5 January 2023', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '10 April 2023', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '25 April 2023', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The authors declare no conflict of interest to this review.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of Interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}